Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$725.99 USD

725.99
1,638,461

-6.21 (-0.85%)

Updated Apr 25, 2024 01:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 16% (211 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for LLY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Eli Lilly and Company falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 2,928 2,212 3,909 3,681 2,439
Receivables 11,336 8,559 8,127 6,929 5,542
Notes Receivable 0 0 0 0 0
Inventories 5,773 4,310 3,886 3,980 3,191
Other Current Assets 5,690 2,954 2,531 2,872 2,539
Total Current Assets 25,727 18,035 18,452 17,462 13,710
Net Property & Equipment 12,914 10,144 8,985 8,682 7,873
Investments & Advances 3,052 2,902 3,213 2,967 1,962
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 5,477 2,793 2,489 2,830 2,573
Intangibles 11,846 11,280 11,584 11,217 10,297
Deposits & Other Assets 4,990 4,337 4,083 3,475 2,339
Total Assets 64,006 49,490 48,806 46,633 39,286
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 6,905 1,501 0 9 1,499
Accounts Payable 2,599 1,931 1,671 1,607 1,405
Current Portion Long-Term Debt 0 0 1,538 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 475 127 495 161
Other Current Liabilities 17,790 13,231 11,717 10,371 8,710
Total Current Liabilities 27,293 17,138 15,053 12,482 11,775
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 87 1,734 2,100 2,188
Convertible Debt 0 0 0 0 0
Long-Term Debt 18,321 14,738 15,346 16,587 13,818
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 7,529 6,751 7,518 9,640 8,320
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 53,143 38,714 39,651 40,808 36,587
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 594 594 596 598 599
Capital Surplus 7,250 6,921 6,833 6,779 6,685
Retained Earnings 10,312 10,043 8,959 7,830 4,920
Other Equity -7,248 -6,732 -7,181 -9,326 -9,445
Treasury Stock 44 51 53 56 61
Total Shareholder's Equity 10,864 10,775 9,155 5,825 2,699
Total Liabilities & Shareholder's Equity 64,006 49,490 48,806 46,633 39,286
Total Common Equity 10,864 10,775 9,155 5,825 2,699
Shares Outstanding 949.30 950.10 956.50 956.50 960.10
Book Value Per Share 11.44 11.34 9.57 6.09 2.81

Fiscal Year End for Eli Lilly and Company falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 2,928 2,494 2,829 3,669
Receivables NA 11,336 10,364 9,171 9,022
Notes Receivable NA 0 0 0 0
Inventories NA 5,773 4,901 4,799 4,545
Other Current Assets NA 5,690 5,248 4,532 3,575
Total Current Assets NA 25,727 23,007 21,332 20,811
Net Property & Equipment NA 12,914 11,863 11,277 10,546
Investments & Advances NA 3,052 2,692 2,745 2,750
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 5,477 4,575 3,806 3,407
Intangibles NA 11,846 10,867 10,982 11,160
Deposits & Other Assets NA 4,990 4,912 4,672 4,488
Total Assets NA 64,006 57,916 54,814 53,163
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 6,905 2,245 662 3
Accounts Payable NA 2,599 2,435 2,474 2,016
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 1,978 1,234 1,528
Other Current Liabilities NA 17,790 15,341 14,545 12,463
Total Current Liabilities NA 27,293 21,998 18,915 16,010
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 18,321 17,924 18,158 18,881
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 6,686 6,591 6,978
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 53,143 46,608 43,665 41,868
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 594 594 594 594
Capital Surplus NA 7,250 7,160 6,949 6,793
Retained Earnings NA 10,312 10,310 10,369 10,639
Other Equity NA -7,248 -6,711 -6,716 -6,686
Treasury Stock NA 44 45 45 45
Total Shareholder's Equity NA 10,864 11,307 11,149 11,295
Total Liabilities & Shareholder's Equity NA 64,006 57,916 54,814 53,163
Total Common Equity 0 10,864 11,307 11,149 11,295
Shares Outstanding 950.10 949.30 949.30 949.20 949.20
Book Value Per Share 0.00 11.44 11.91 11.75 11.90